{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/71fb798f\"></iframe>","width":"100%","height":180,"duration":3413,"description":"\nIn this episode, we dive deep into ASH 2025 updates on myeloid malignancies with Dr. Curtis Lachowiez. From the plenary halls of ASH 2025 to long-term follow-up of Aza/Ven/Gilteritinib, we unpack what the latest evidence means for the future of AML management.\n\n1. PARADIGM Trial (Plenary Session, Abstract 6)\nFathi A, Perl A, Fell G, et al. Results from PARADIGM – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood 2025;146(Suppl 1):6.\nhttps://doi.org/10.1182/blood-2025-6\nClinicalTrials.gov: NCT04801797\n\n2. VICEROY Study – Aza/Ven/Gilteritinib Triplet (Abstract 654)\nVenetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy: Interim results from the phase 1/2 VICEROY study. Blood 2025;146(Suppl 1):654.\nClinicalTrials.gov: NCT05520567\n\n3. Long-Term Follow-Up of Aza/Ven/Gilteritinib in FLT3-Mutated AML (Abstract 45)\nAzevedo RS, et al. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Blood 2025;146(Suppl 1):45.\nOriginal publication: Short NJ, Daver N, DiNardo CD, et al. J Clin Oncol 2024;42:1499–1508. https://doi.org/10.1200/JCO.23.01911\nClinicalTrials.gov: NCT04140487\n\n4. PRISM-AML Score (Abstract 453)\nLachowiez CA, et al. Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study. Blood 2025;146(Suppl 1):453.\nInteractive Calculator: https://prism-aml.com\n\n5. Additional Studies Referenced in Discussion\n•       VIALE-A Trial: DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617–629. (NCT02993523)\n•       VERONA Trial: Randomized study of Aza-Ven vs. Aza vs. placebo in MDS (discussed...","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}